Shots:
- Merck has reported P-III (VICTOR) trial data assessing Verquvo (n=3,053) vs PBO (n=3,052) in pts with stable chronic heart failure & reduced ejection fraction
- Trial did not meet its 1EPs of reducing CV death or HF hospitalization (18% vs 19.1%); however, 2EPs showed numerically lower rates of CV death (9.6% vs 11.3%) & HF hospitalization (11.4% vs 11.9%)
- Although, pooled analysis of P-III (VICTOR & VICTORIA) trials (n=11,155) showed Verquvo reduced risk of the composite endpoint & its secondary components across a broad HF population; both analyses were presented at ESC’25 & published in The Lancet
Ref: Merck | Image: Merck | Press Release
Related News:- Daiichi Sankyo and Merck Dose First Patient in P-III (HERTHENA-Breast04) Trial of Patritumab Deruxtecan to Treat HR+/HER2- Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
